Cancer Immunotherapy is one of the topics we will be talking about a lot on the podcast. As we gear up to the first episode, we thought we would share a few stories that set the scene, what we are calling a prologue.
In this audio piece, you will hear Daniel Chen MD PhD (pictured right), Cancer Immunotherapy Head at Roche Genentech talk about how our immune system can be used to fight cancer.
The interview took place at the 2014 annual meeting of the Society for Immunotherapy of Cancer (SITC).
It focuses on checkpoint inhibition, which along with Chimeric Antigen Receptor T Cell therapy, is one of the hottest areas in cancer immunotherapy research.
Promising results have been obtained with checkpoint inhibitors that act against the programmed cell death protein (PD-1) and its ligand (PD-L1) by unmasking the cancer cells, removing their “Klingon cloak” of disguise and invisibility. They enable T cells, a type of white blood cell, to recognize and kill the cancer cell.
The interview was broadcast in the December 7, 2014 edition of the Sound Medicine Radio Hour, a public radio show distributed by WFYI in Indianapolis.
Disclosure: Dr Chen is an employee of Roche Genentech, a sponsor of the podcast. He is also an expert in cancer immunotherapy, adjunct faculty in medical oncology at Stanford, and was interviewed based on his qualifications, knowledge and ability to communicate science & medicine.
If you haven’t already seen it, this video from Roche Genentech narrated by Dr Chen is well worth watching. It is educational and discusses the mechanism of action of their anti-PDL1 monoclonal antibody, MPDL3280A. We think it’s great fun and entertaining to watch. Enjoy!
You can read more about the latest developments in Immuno-Oncology on Biotech Strategy Blog (subscription required).
© Blue Ice Publishing LLC. All Rights Reserved.